文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

血必净注射液与安慰剂治疗重症社区获得性肺炎危重患者:一项随机对照试验

XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论在重症社区获得性肺炎危重患者中,血必净注射液100 mL每12小时一次可显著改善肺炎严重指数风险评级、28天死亡率、机械通气时间和ICU住院时间。

这项前瞻性随机对照研究在中国33家医院纳入710例18-75岁重症社区获得性肺炎成人患者,血必净组接受血必净100 mL每12小时一次,对照组接受外观不可区分的安慰剂。主要终点为8天肺炎严重指数风险评级改善,血必净组203例(60.78%)vs 安慰剂组158例(46.33%),组间差异14.4%(95%CI 6.9-21.8%),P<0.001。28天死亡率血必净组53例(15.87%)vs 安慰剂组84例(24.63%),差异8.8%(95%CI 2.4-15.2%),P=0.006;血必净还缩短了机械通气时间(中位11.0天 vs 16.5天,P=0.012)和ICU总住院时间(12天 vs 16天,P=0.004)。不良事件发生率两组无显著差异(35.63% vs 40.18%,P=0.235)。

要点

  • 血必净组8天肺炎严重指数风险评级改善率60.78%(203例)vs 安慰剂组46.33%(158例),组间差异14.4%(95%CI 6.9-21.8%),P<0.001。
  • 28天死亡率血必净组15.87%(53例)vs 安慰剂组24.63%(84例),差异8.8%(95%CI 2.4-15.2%),P=0.006。
  • 中位机械通气时间血必净组11.0天 vs 安慰剂组16.5天(P=0.012),ICU总住院时间12天 vs 16天(P=0.004)。
  • 不良事件发生率血必净组35.63%(119例)vs 安慰剂组40.18%(137例),P=0.235,两组无显著差异。

适用人群与场景

  • 中国33家医院中18-75岁重症社区获得性肺炎成人患者。

处置流程与药物剂量

  • 血必净组接受血必净注射液100 mL,每12小时一次,对照组接受外观不可区分的安慰剂。

研究设计与关键结果

  • 研究为前瞻性随机对照研究,纳入710例重症社区获得性肺炎成人患者,血必净组接受血必净100 mL每12小时一次,对照组接受安慰剂。
  • 主要终点8天肺炎严重指数风险评级改善:血必净组203例(60.78%)vs 安慰剂组158例(46.33%),组间差异14.4%(95%CI 6.9-21.8%),P<0.001。
  • 28天死亡率:血必净组53例(15.87%)vs 安慰剂组84例(24.63%),差异8.8%(95%CI 2.4-15.2%),P=0.006。
  • 中位机械通气时间:血必净组11.0天 vs 安慰剂组16.5天,P=0.012。
  • ICU总住院时间:血必净组12天 vs 安慰剂组16天,P=0.004。
  • 不良事件:血必净组119例(35.63%)vs 安慰剂组137例(40.18%),P=0.235。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于18-75岁重症社区获得性肺炎成人患者,血必净注射液100 mL每12小时一次可能改善8天肺炎严重指数风险评级、降低28天死亡率、缩短机械通气时间和ICU住院时间;作者认为该结果支持血必净在此类患者中的应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To investigate whether XueBiJing injection improves clinical outcomes in critically ill patients with severe community-acquired pneumonia.

DESIGN: Prospective, randomized, controlled study.

SETTING: Thirty-three hospitals in China.

PATIENTS: A total of 710 adults 18-75 years old with severe community-acquired pneumonia.

INTERVENTIONS: Participants in the XueBiJing group received XueBiJing, 100 mL, q12 hours, and the control group received a visually indistinguishable placebo.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was 8-day improvement in the pneumonia severity index risk rating. Secondary outcomes were 28-day mortality rate, duration of mechanical ventilation and total duration of ICU stay. Improvement in the pneumonia severity index risk rating, from a previously defined endpoint, occurred in 203 (60.78%) participants receiving XueBiJing and in 158 (46.33%) participants receiving placebo (between-group difference [95% CI], 14.4% [6.9-21.8%]; p < 0.001). Fifty-three (15.87%) XueBiJing recipients and 84 (24.63%) placebo recipients (8.8% [2.4-15.2%]; p = 0.006) died within 28 days. XueBiJing administration also decreased the mechanical ventilation time and the total ICU stay duration. The median mechanical ventilation time was 11.0 versus 16.5 days for the XueBiJing and placebo groups, respectively (p = 0.012). The total duration of ICU stay was 12 days for XueBiJing recipients versus 16 days for placebo recipients (p = 0.004). A total of 256 patients experienced adverse events (119 [35.63%] vs 137 [40.18%] in the XueBiJing and placebo groups, respectively [p = 0.235]).

CONCLUSIONS: In critically ill patients with severe community-acquired pneumonia, XueBiJing injection led to a statistically significant improvement in the primary endpoint of the pneumonia severity index as well a significant improvement in the secondary clinical outcomes of mortality, duration of mechanical ventilation and duration of ICU stay.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Song Y, Yao C, Yao Y, et al. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med. 2019. PMID: 31162191. doi:10.1097/CCM.0000000000003842

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。